BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31651209)

  • 21. Effect and mechanisms of celastrol on the apoptosis of HOS osteosarcoma cells.
    Chen Y; Ou Y; Tao Y; Liu H; Yin H; Zhong S; Yu H; Zhao Z; He B
    Oncol Rep; 2018 Oct; 40(4):2260-2268. PubMed ID: 30106429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of LINC01419 in regulating the cell stemness in lung adenocarcinoma through recruiting EZH2 and regulating FBP1 expression.
    Chen Z; Tang W; Zhou Y; He Z
    Biol Direct; 2022 Sep; 17(1):23. PubMed ID: 36050791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p.
    Cao J; Han X; Qi X; Jin X; Li X
    Int J Oncol; 2017 Oct; 51(4):1115-1123. PubMed ID: 28902349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LINC01116 promotes proliferation, invasion and migration of osteosarcoma cells by silencing p53 and EZH2.
    Zhang ZF; Xu HH; Hu WH; Hu TY; Wang XB
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6813-6823. PubMed ID: 31486480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-101 inhibits the metastasis of osteosarcoma cells by downregulation of EZH2 expression.
    Zhang K; Zhang Y; Ren K; Zhao G; Yan K; Ma B
    Oncol Rep; 2014 Nov; 32(5):2143-9. PubMed ID: 25190211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paternal genome rescues mouse preimplantation embryo development in the absence of maternally-recruited EZH2 activity.
    Wang H; Paulson EE; Ma L; Ross PJ; Schultz RM
    Epigenetics; 2019 Jan; 14(1):94-108. PubMed ID: 30661456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
    Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
    Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth.
    Sasaki H; Setoguchi T; Matsunoshita Y; Gao H; Hirotsu M; Komiya S
    Oncol Rep; 2010 Mar; 23(3):677-84. PubMed ID: 20127006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
    Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
    Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EZH2 inhibitor GSK343 inhibits sepsis-induced intestinal disorders.
    Yue D; Wang Z; Yang Y; Hu Z; Luo G; Wang F
    Exp Ther Med; 2021 May; 21(5):437. PubMed ID: 33747174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expressions of EZH2 and NOTCH3 pathway in osteosarcoma and their roles in osteosarcoma stem cells.
    Yan G; Lv Y; Lai X; Li Z; Ye D; Wang W; Qian Y; Yu H; Wang Z
    Pol J Pathol; 2022; 73(4):343-351. PubMed ID: 36946271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2.
    Yang L; Ge D; Chen X; Qiu J; Yin Z; Zheng S; Jiang C
    Biochem Biophys Res Commun; 2018 Aug; 502(4):493-500. PubMed ID: 29859193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas.
    Lindsay CD; Kostiuk MA; Harris J; O'Connell DA; Seikaly H; Biron VL
    Clin Epigenetics; 2017; 9():95. PubMed ID: 28878842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells.
    Yu T; Wang Y; Hu Q; Wu W; Wu Y; Wei W; Han D; You Y; Lin N; Liu N
    Oncotarget; 2017 Nov; 8(58):98348-98359. PubMed ID: 29228694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long noncoding RNA HOXD-AS1 aggravates osteosarcoma carcinogenesis through epigenetically inhibiting p57 via EZH2.
    Gu W; Zhang E; Song L; Tu L; Wang Z; Tian F; Aikenmu K; Chu G; Zhao J
    Biomed Pharmacother; 2018 Oct; 106():890-895. PubMed ID: 30119259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of EZH2 mitigates peritoneal fibrosis and lipid precipitation in peritoneal mesothelial cells mediated by klotho.
    Wang Q; Sun J; Wang R; Sun J
    Ren Fail; 2023 Dec; 45(1):2149411. PubMed ID: 36724065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinobufagin induces autophagy-mediated cell death in human osteosarcoma U2OS cells through the ROS/JNK/p38 signaling pathway.
    Ma K; Zhang C; Huang MY; Li WY; Hu GQ
    Oncol Rep; 2016 Jul; 36(1):90-8. PubMed ID: 27176794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.
    Lv YF; Yan GN; Meng G; Zhang X; Guo QN
    Sci Rep; 2015 Aug; 5():12999. PubMed ID: 26265454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
    Barazeghi E; Hellman P; Norlén O; Westin G; Stålberg P
    Sci Rep; 2021 Nov; 11(1):22733. PubMed ID: 34815475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.
    Cao J; Pontes KC; Heijkants RC; Brouwer NJ; Groenewoud A; Jordanova ES; Marinkovic M; van Duinen S; Teunisse AF; Verdijk RM; Snaar-Jagalska E; Jochemsen AG; Jager MJ
    J Pathol; 2018 Aug; 245(4):433-444. PubMed ID: 29732557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.